219 related articles for article (PubMed ID: 16961463)
1. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
Chase A; Cross NC
Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463
[TBL] [Abstract][Full Text] [Related]
2. Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.
Chalandon Y; Schwaller J
Haematologica; 2005 Jul; 90(7):949-68. PubMed ID: 15996933
[TBL] [Abstract][Full Text] [Related]
3. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
4. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
Zhu N; Xiao H; Wang LM; Fu S; Zhao C; Huang H
Future Oncol; 2015; 11(4):659-73. PubMed ID: 25686120
[TBL] [Abstract][Full Text] [Related]
5. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Ernst T; Erben P; Müller MC; Paschka P; Schenk T; Hoffmann J; Kreil S; La Rosée P; Hehlmann R; Hochhaus A
Haematologica; 2008 Feb; 93(2):186-92. PubMed ID: 18223278
[TBL] [Abstract][Full Text] [Related]
7. Flying under the radar: the new wave of BCR-ABL inhibitors.
Quintás-Cardama A; Kantarjian H; Cortes J
Nat Rev Drug Discov; 2007 Oct; 6(10):834-48. PubMed ID: 17853901
[TBL] [Abstract][Full Text] [Related]
8. Applying the discovery of the Philadelphia chromosome.
Sherbenou DW; Druker BJ
J Clin Invest; 2007 Aug; 117(8):2067-74. PubMed ID: 17671641
[TBL] [Abstract][Full Text] [Related]
9. ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Ernst T; Hoffmann J; Erben P; Hanfstein B; Leitner A; Hehlmann R; Hochhaus A; Müller MC
Haematologica; 2008 Sep; 93(9):1389-93. PubMed ID: 18603549
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
Agarwal MB
J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
[No Abstract] [Full Text] [Related]
11. Imatinib resistance in CML.
Volpe G; Panuzzo C; Ulisciani S; Cilloni D
Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
[TBL] [Abstract][Full Text] [Related]
12. Role of tyrosine kinase inhibitors in cancer therapy.
Arora A; Scholar EM
J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
[TBL] [Abstract][Full Text] [Related]
13. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
15. Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.
Beel K; Janssens A; Verhoef G; Vandenberghe P
Leuk Res; 2009 Dec; 33(12):1703-5. PubMed ID: 19457553
[TBL] [Abstract][Full Text] [Related]
16. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
18. Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.
Nardi V; Raz T; Cao X; Wu CJ; Stone RM; Cortes J; Deininger MW; Church G; Zhu J; Daley GQ
Oncogene; 2008 Jan; 27(6):775-82. PubMed ID: 17684485
[TBL] [Abstract][Full Text] [Related]
19. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
20. Roots of imatinib resistance: a question of self-renewal?
Burchert A
Drug Resist Updat; 2007; 10(4-5):152-61. PubMed ID: 17683977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]